Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a laboratory-confirmed diagnosis of a type of lung cancer called ALK-positive non-small cell lung cancer (NSCLC)
- People whose cancer can be measured on scans according to a standard set of rules called RECIST v1.1
- People whose blood counts and organ function (such as liver and kidneys) are within acceptable levels
- Part 1 and Part 2 Cohort M1: People who have previously been treated with 2 to 3 ALK-targeting drugs, including one called lorlatinib, but where lorlatinib was not the very first treatment given
- Part 2 Cohort M1 (additional requirement): People who have not previously received a drug called neladalkib
- Part 2 Cohort M2: People who have previously been treated with more than 3 ALK-targeting drugs, including both lorlatinib and neladalkib, where neither of those two drugs was the very first treatment given
- Part 2 Cohort M3: People who have never previously been treated with any ALK-targeting drugs
Who may not be able to join:
- People whose cancer has certain additional genetic changes that are known to cause resistance to ALK-targeting drugs
- People who have cancer that has spread to the brain or spinal cord and is causing worsening neurological symptoms, or where increasing doses of steroid medications are needed to manage those symptoms
- People who are currently receiving any other cancer treatment or are taking part in another clinical trial involving an experimental treatment
- People who have a known allergy or sensitivity to the trial drug TRI-611 or any of its components
- People who have had major surgery within 4 weeks before the first dose of the trial drug would be given
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Treatment emergent adverse events; Part 2: Objective response rate (ORR); Part 2: Depth of response (DofR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.